| 1. |
- Thomas, HS, et al.
(författare)
-
- 2019
-
swepub:Mat__t
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
|
|
| 16. |
- Abouelela, M. E., et al.
(författare)
-
Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus Aloe: An In Silico Study for Drug Development
- 2021
-
Ingår i: Molecules. - : MDPI AG. - 1420-3049. ; 26:6
-
Tidskriftsartikel (refereegranskat)abstract
- Severe acute respiratory syndrome coronavirus (SARS-CoV-2) disease is a global rapidly spreading virus showing very high rates of complications and mortality. Till now, there is no effective specific treatment for the disease. Aloe is a rich source of isolated phytoconstituents that have an enormous range of biological activities. Since there are no available experimental techniques to examine these compounds for antiviral activity against SARS-CoV-2, we employed an in silico approach involving molecular docking, dynamics simulation, and binding free energy calculation using SARS-CoV-2 essential proteins as main protease and spike protein to identify lead compounds from Aloe that may help in novel drug discovery. Results retrieved from docking and molecular dynamics simulation suggested a number of promising inhibitors from Aloe. Root mean square deviation (RMSD) and root mean square fluctuation (RMSF) calculations indicated that compounds 132, 134, and 159 were the best scoring compounds against main protease, while compounds 115, 120, and 131 were the best scoring ones against spike glycoprotein. Compounds 120 and 131 were able to achieve significant stability and binding free energies during molecular dynamics simulation. In addition, the highest scoring compounds were investigated for their pharmacokinetic properties and drug-likeness. The Aloe compounds are promising active phytoconstituents for drug development for SARS-CoV-2.
|
|
| 17. |
- Ashour, Radwa M., et al.
(författare)
-
Rare Earth Ions Adsorption onto Graphene Oxide Nanosheets
- 2017
-
Ingår i: Solvent extraction and ion exchange. - : Informa UK Limited. - 0736-6299 .- 1532-2262. ; 35:2, s. 91-103
-
Tidskriftsartikel (refereegranskat)abstract
- Graphene oxide (GO) was synthesized and used as a coagulant of rare earth elements (REEs) from aqueous solution. Stability and adsorption capacities were exhibited for target REEs such as La(III), Nd(III), Gd(III), and Y(III). The parameters influencing the adsorption capacity of the target species including contact time, pH, initial concentration, and temperature were optimized. The adsorption kinetics and thermodynamics were studied. The method showed quantitative recovery (99%) upon desorption using HNO3 acid (0.1 M) after a short contact time (15 min).
|
|
| 18. |
|
|
| 19. |
- Adamo, Marianna, et al.
(författare)
-
Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC
- 2024
-
Ingår i: European Journal of Heart Failure. - : WILEY. - 1388-9842 .- 1879-0844.
-
Tidskriftsartikel (refereegranskat)abstract
- Right-sided heart failure and tricuspid regurgitation are common and strongly associated with poor quality of life and an increased risk of heart failure hospitalizations and death. While medical therapy for right-sided heart failure is limited, treatment options for tricuspid regurgitation include surgery and, based on recent developments, several transcatheter interventions. However, the patients who might benefit from tricuspid valve interventions are yet unknown, as is the ideal time for these treatments given the paucity of clinical evidence. In this context, it is crucial to elucidate aetiology and pathophysiological mechanisms leading to right-sided heart failure and tricuspid regurgitation in order to recognize when tricuspid regurgitation is a mere bystander and when it can cause or contribute to heart failure progression. Notably, early identification of right heart failure and tricuspid regurgitation may be crucial and optimal management requires knowledge about the different mechanisms and causes, clinical course and presentation, as well as possible treatment options. The aim of this clinical consensus statement is to summarize current knowledge about epidemiology, pathophysiology and treatment of tricuspid regurgitation in right-sided heart failure providing practical suggestions for patient identification and management.
|
|
| 20. |
|
|
| 21. |
|
|
| 22. |
|
|
| 23. |
- Rosano, Giuseppe M. C., et al.
(författare)
-
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
- 2021
-
Ingår i: European Journal of Heart Failure. - : Wiley-Blackwell. - 1388-9842 .- 1879-0844. ; 23:6, s. 872-881
-
Tidskriftsartikel (refereegranskat)abstract
- Despite guideline recommendations and available evidence, implementation of treatment in heart failure (HF) is poor. The majority of patients are not prescribed drugs at target doses that have been proven to positively impact morbidity and mortality. Among others, tolerability issues related to low blood pressure, heart rate, impaired renal function or hyperkalaemia are responsible. Chronic kidney disease plays an important role as it affects up to 50% of patients with HF. Also, dynamic changes in estimated glomerular filtration rate may occur during the course of HF, resulting in inappropriate dose reduction or even discontinuation of decongestive or neurohormonal modulating therapy in clinical practice. As patients with HF are rarely naive to pharmacologic therapies, the challenge is to adequately prioritize or select the most appropriate up-titration schedule according to patient profile. In this consensus document, we identified nine patient profiles that may be relevant for treatment implementation in HF patients with a reduced ejection fraction. These profiles take into account heart rate (70 bpm), the presence of atrial fibrillation, symptomatic low blood pressure, estimated glomerular filtration rate (30 mL/min/1.73 m(2)) or hyperkalaemia. The pre-discharge patient, frequently still congestive, is also addressed. A personalized approach, adjusting guideline-directed medical therapy to patient profile, may allow to achieve a better and more comprehensive therapy for each individual patient than the more traditional, forced titration of each drug class before initiating treatment with the next.
|
|
| 24. |
- Abdel-Magied, Ahmed Fawzy, et al.
(författare)
-
Hierarchical porous zeolitic imidazolate framework nanoparticles for efficient adsorption of rare-earth elements
- 2019
-
Ingår i: Microporous and Mesoporous Materials. - : Elsevier. - 1387-1811 .- 1873-3093. ; 278, s. 175-184
-
Tidskriftsartikel (refereegranskat)abstract
- Hierarchical porous zeolitic imidazolate frameworks nanoparticles (ZIF-8 NPs) were synthesized at room temperature via a template-free approach under dynamic conditions (stirring) using water as a solvent. The ZIF-8 NPs were evaluated as adsorbents for rare earth elements (La3+, Sm3+ and Dy3+). Adsorption equilibrium was reached after 7h and high adsorption capacities were obtained for dysprosium and samarium (430.4 and 281.1 mg g(-1), respectively) and moderate adsorption capacity for lanthanum (28.8 mg g(-1)) at a pH of 7.0. The high adsorption capacitiese, as well as the high stability of ZIF-8 NPs, make the hierarchical ZIF-8 materials as an efficient adsorbent for the recovery of La3+, Sm3+ and Dy3+ from aqueous solution.
|
|
| 25. |
|
|
